CANTON, Mass., July 20 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ), developer of the world's first oral fluid on-site disposable test for drugs- of-abuse, announces the acceleration of new client additions which has resulted in 95 new clients through the first three quarters of its current fiscal year.
"We are beginning to realize the benefits of our investment in sales and marketing resources," said Peter P. Phildius, Chairman and CEO of Avitar. "With our sales and marketing management in place, we have developed a new strategy as well as a message that is gaining traction in the marketplace and our sales force is communicating that message effectively. With the average tenure of our sales staff being only several months due to new hires, the rapid growth in the number of new clients is even more significant."
Mr. Phildius continued, "Both the corporate and government sectors are beginning to understand the importance of oral fluid technology as a critical component to the solution of America's drug problem. Adulteration of traditional lab-based urine tests has become widely known as evidenced in the press and recent meetings on Capitol Hill. Oral fluid drug screening virtually eliminates altering test results, is less costly, and more convenient to use in a workplace."
Additionally Avitar introduced its second generation point-of-care test, the Drugometer(TM), during this period, which is also contributing to Avitar's growth.
About Avitar
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Their field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen®, the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement.
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Company Contact: PR Contact:
Peter Cholakis Monica Pandolfi
Avitar Technologies, Inc. Shift Communications
x117
IR Contact:
Lisa DeScenza
LaVoie Group
